Advertisement

Journal of Anesthesia

, Volume 6, Issue 1, pp 28–37 | Cite as

Pharmacokinetics and pharmacodynamics of vecuronium bromide

  • Toshiyuki Nomura
Original Articles

Abstract

The pharmacokinetics and pharmacodynamics of vecuronium bromide were studied in patients under general anesthesia of enflurane and nitrous oxide in oxygen. Eighteen patients were randomly divided into two groups which received either 0.05 mg·kg−1 (low dose group) or 0.20 mg·kg−1 (high dose group) of vecuronium intravenously. The plasma concentration of vecuronium was determined by high performance liquid chromatography. The neuromuscular blocking effect was assessed by measuring the twitch tension of the adductor pollicis muscle elicited by supramaximal electrical stimulation. Pharmacokinetic analysis was carried out using a two compartment model.

The relationship between the T4/T1 and T1/control T1 ratios differed during onset and spontaneous offset of the blockade; the T4/T1 ratios were significantly higher during onset than during offset, although there were large variations of fade in the train-of-four response in each patient during offset. These results suggest that it is difficult to estimate the T1/control T1 ratio by the T4/T1 ratio during offset.

Pharmacokinetic analysis revealed that the high dose group had a shorter elimination half-life than did the low dose group. A shorter elimination half-life at a high dose may be to some extent due to hepatic clearance. The pharmacokinetic parameters bore no fixed relationship to the pharmacodynamics in each patient.

Key words

vecuronium bromide pharmacokinetics pharmacodynamics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Paanakker JE, Van de Laar GLM: Determination of Org NC 45 (a myoneural blocking agent) in human plasma using high-performance normal-phase liquid chromato-graphy. J Chromatogr 183:459–466, 1980CrossRefPubMedGoogle Scholar
  2. 2.
    Bowman WC: Prejunctional and postjunctional cholinoceptors at the neuromuscular junction. Anesth Analg 59:935–943, 1980CrossRefPubMedGoogle Scholar
  3. 3.
    Pearce AC, Casson WR, Jones RM: Factors affecting train-of-four fade. Br J Anaesth 57:602–606, 1985CrossRefPubMedGoogle Scholar
  4. 4.
    Ali HH, Savarese JJ, Lebowitz PW, et al: Twitch, tetanus and train-offour as indices of recovery from nondepolarizing neuromuscular blockade. Anesthesiology 54:294–297, 1981CrossRefPubMedGoogle Scholar
  5. 5.
    Van der Veen F, Bencini A: Pharmacokinetics and pharmacodynamics of Org NC 45 in man. Br J Anaesth 52:37S-41S, 1980CrossRefPubMedGoogle Scholar
  6. 6.
    Fahey MR, Morris RB, Miller RD, et al: Pharmacokinetics of Org NC45 (NORCURON) in patients with and without renal failure. Br J Anaesth 53: 1049–1053, 1981CrossRefPubMedGoogle Scholar
  7. 7.
    Yajima C, Sugai N, Inada Y: Pharmacokinetics and pharmacodynamics of vecuronium and pancuronium in anesthetized man. Masui (Jpn J Anesth) 34: 1245–1251, 1985Google Scholar
  8. 8.
    Hunter JM, Parker CJR, Bell CF, et al: The use of different doses of vecuronium in patients with liver disfunction. Br J Anaesth 57: 758–764, 1985CrossRefPubMedGoogle Scholar
  9. 9.
    Bencini AF, Scaf AHJ, Sohn YJ, et al: Disposition and urinary excretion of vecuronium bromide in anesthetized patients with normal renal function or renal failure. Anesth Analg 65:245–251, 1986CrossRefPubMedGoogle Scholar
  10. 10.
    Lebrault C, Berger JL, D’Hollander AA, et al: Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) in patients with cirrhosis. Anesthesiology 62:601–605, 1985CrossRefPubMedGoogle Scholar
  11. 11.
    Arden JR, Lynam DP, Castagnoli KP, et al: Vecuronium in alcoholic liver disease: a pharmacokinetic and pharmacodynamic analysis. Anesthesiology 68:771–776, 1988CrossRefPubMedGoogle Scholar
  12. 12.
    Lynam DP, Cronnelly R, Castagnoli KP, et al: The pharmacodynamics and pharmacokinetics of vecuronium in patients anesthetized with isoflurane with normal renal function or with renal failure. Anesthesiology 69:227–231, 1988CrossRefPubMedGoogle Scholar
  13. 13.
    McLeod K, Watoson MJ, Rawlins MD: Pharmacokinetics of pancuronium in patients with normal and impaired renal function. Br J Anaesth 48:341–345, 1976CrossRefPubMedGoogle Scholar
  14. 14.
    Somogyi AA, Shanks CA, Triggs EJ: Disposition kinetics of pancuronium bromide in patients with total biliary obstruction. Br J Anaesth 49:1103–1108, 1977CrossRefPubMedGoogle Scholar
  15. 15.
    Miller RD, Agoston S, Booij LHDJ, et al: The comparative potency and pharmacokinetics of pancuronium and its metabolites in anesthetized man. J Pharmacol Exp Ther 207:539–543, 1978PubMedGoogle Scholar
  16. 16.
    Hull CJ, English MJM, Sibbald A: Faradium and pancuronium: a pharmacodynamic study. Br J Anaesth 52:1209–1221, 1980CrossRefPubMedGoogle Scholar
  17. 17.
    Duvaldestin P, Saada J, Berger JL, et al: Pharmacokinetics, pharmacodynamics, and dose-response relationships of pancuronium in control and elderly subjects. Anesthesiology 56:36–40, 1982CrossRefPubMedGoogle Scholar
  18. 18.
    Cronnelly R, Fisher DM, Miller RD, et al: Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) and pancuronium in anesthetized humans. Anesthesiology 58:405–408, 1983CrossRefPubMedGoogle Scholar
  19. 19.
    Booij LHDJ, Vree TB, Hurkmans F, et al: Pharmacokinetics and pharmacodynamics of the muscle relaxant drug Org NC-45 and each of its hydroxy metabolites in dogs. Anaesthesist 30:329–333, 1981PubMedGoogle Scholar
  20. 20.
    Upton RA, Nguyen TL, Miller RD, et al: Renal and biliary elimination of vecuronium (ORG NC45) and pancuronium in rats. Anesth Analg 61:313–316, 1982CrossRefPubMedGoogle Scholar
  21. 21.
    Bencini AF, Scaf AHJ, Agoston S, et al: Disposition of vecuronium bromide in the cat. Br J Anaesth 57:782–788, 1985CrossRefPubMedGoogle Scholar
  22. 22.
    Bencini AF, Houwertjes MC, Agoston S: Effects of hepatic uptake of vecuronium bromide and its putative metabolites on their neuromuscular blocking actions in the cat. Br J Anaesth 57:789–795, 1985CrossRefPubMedGoogle Scholar
  23. 23.
    Bencini AF, Mol WEM, Scaf AHJ, et al: Uptake and excretion of vecuronium bromide and pancuronium bromide in the isolated perfused rat liver. Anesthesiology 69:487–492, 1988CrossRefPubMedGoogle Scholar
  24. 24.
    Bencini AF, Scaf AHJ, Sohn YJ, et al: Hepatobiliary disposition of vecuronium bromide in man. Br J Anaesth 58:988–995, 1986CrossRefPubMedGoogle Scholar
  25. 25.
    Savage DS, Sleigh T, Carlyle I: The emergence of Org NC45, 1-[(2,β, 3α, 5α, 16,β, 17,β)-3, 17-bis(acetyloxy)-2-(1-piperidinyl)-androstan 16-yl]-1-methyl-piperidinium bromide, from the pancuronium series. Br J Anaesth 52:3S-9S, 1980CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Anesthesiologists 1992

Authors and Affiliations

  • Toshiyuki Nomura
    • 1
  1. 1.Department of Anesthesiology, School of MedicineKanazawa UniversityKanazawaJapan

Personalised recommendations